Clinical trial

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

NCT00730639

Drugs and interventions used in this trial

5 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

BIOLOGICAL · Unmapped registry intervention BMS-936558 (MDX-1106) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE1

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2008-10-30

PhasePHASE1

Conditions

Metastatic Castration-resistant Prostrate Cancerunresolved

Renal Cell Carcinomaverified · MONDO: renal cell carcinoma

Metastatic Melanomaverified · MONDO: metastatic melanoma

Non-small Cell Lung Cancerverified · MONDO: non-small cell lung carcinoma

Interventions

BMS-936558 (MDX-1106)BIOLOGICAL

Sponsors & collaborators

Bristol-Myers Squibblead sponsor

Ono Pharmaceutical Co., Ltd.collaborator

Mapped research locations

BostonMassachusetts, United States3 NashvilleTennessee, United States2 New YorkNew York, United States1 BaltimoreMaryland, United States1 CincinnatiOhio, United States1 TampaFlorida, United States1 Ann ArborMichigan, United States1 New HavenConnecticut, United States1 ScottsdaleArizona, United States1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT00730639 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.